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Two years have passed since crizotinib, the first anaplastic lymphoma kinase (ALK) inhibitor, was approved based on the results of a phase II study (profile 1005).1 Now, 
results of a phase III study of crizotinib versus chemotherapy are also available, which 
show that the inhibitor significantly prolongs PFS as compared with standard single-agent 
chemotherapy in patients previously treated with first-line platinum-based chemotherapy.1 
Recently, it was shown that this agent is also superior to standard first-line pemetrexed-
plus-platinum chemotherapy.2 In addition to crizotinib, so-called second-generation ALK 
inhibitors have been developed and are being used in clinical practice in some countries, 
based on high efficacy shown in phase I/II studies.3,4 Accordingly, treatment with an ALK 
inhibitor is now recognized as a standard care regimen, whereas it has also become increas-
ingly important to appropriately select patients with the alteration. Break-apart fluorescent 
in-situ hybridization (FISH) is currently the only diagnostic tool approved by the FDA; 
however, the low incidence of ALK rearrangement (about 4% in non–small-cell lung cancer 
[NSCLC]) requires a more rapid and cost-efficient method for screening. Many countries 
have adopted immunohistochemistry (IHC) screening followed by FISH confirmation.5 
Figure 1 shows the diagnostic algorithm of ALK rearrangement used by the Japanese Lung 
Cancer Society6 and this workflow has been recommended in the molecular testing guide-
lines provided by CAP/IASLC/AMP.7
For effective screening, high sensitivity is essential and ALK IHC is considered to 
meet that requirement, as a very high concordance between IHC and FISH results have 
been reported. However, recent large-scaled studies have also found more than a few cases 
with discordant results between IHC and FISH (Table 1). Blackhall et al.8 recently reported 
52 cases with discrepant results in simultaneous examinations of ALK using IHC and FISH 
in a matched cohort of 240 NSCLC cases. In their study, eight of the samples with discrep-
ant results were subjected to reverse transcription-polymerase chain reaction, of which six 
were concordant with FISH results, whereas IHC+/FISH- cases were positive and IHC-/
FISH+ cases were negative for detection of the fusion transcript. Pfizer Japan conducted a 
prereimbursement program,9 in which ALK testing and crizotinib were provided for free 
to compensate for ethical conflicts with patients diagnosed as ALK positive during the 
3 months between drug approval and price listing in the national health care reimburse-
ment system. Among the 2337 tumors simultaneously examined with IHC and FISH, 48 
showed discrepant results, including 12 classified as IHC+/FISH- and 36 as IHC-/FISH+. 
Re-analysis of these tumors by the Biomarker Committee of the Japanese Lung Cancer 
Society revealed that all tissue-available tumors with IHC+/FISH- results were incorrectly 
diagnosed, whereas 21 of 29 IHC-/FISH+ results were not overturned. Notably, progressive 
disease was shown in 9 of 15 of the patients with discrepant results who were treated with 
crizotinib. Cabillic et al.10 also simultaneously examined 3244 consecutive NSCLC speci-
mens with IHC and FISH, and found 19 IHC+/FISH- and 36 IHC-/FISH+ cases. In contrast 
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to the Japanese study, only one case showed progressive dis-
ease. Also, in a recent study by Ali et al.,11 two IHC-/FISH+ 
cases were identified in examinations of 523 NSCLCs sub-
jected to simultaneous IHC and FISH analyses. MassARRAY 
and reverse transcription polymerase chain reaction assays 
were used to examine two of the cases with discordant results, 
which revealed a negative fusion transcript. Taken together, 
these results show that not a few cases with IHC/FISH dis-
crepant results exist in clinical practice.
As for discrepancies between IHC and FISH, some 
possible causes have been proposed (Table 2). Intracellular 
and extracellular mucin can cause false-negative and false-
positive results, respectively, in IHC analysis. Just as in 
normal ganglion cells, neuroendocrine tumors including 
small-cell lung cancer express ALK without ALK altera-
tions. In terms of FISH, atypical FISH signals, such as a 3′-
5′-3′ red doublet pattern, and compressed z-stacked images 
for vertically split signals may give false-negative results. In 
addition, it has been revealed that specimens with discordant 
IHC/FISH results commonly harbor a borderline percentage 
of break-apart signals. Currently, ALK FISH is considered to 
be positive when split and/or single red signals are detected 
in more than 15% of the tumor cells. Ilie et al.12 reported 
that in both IHC-/FISH+ and IHC+/FISH- discrepant cases, 
the percentage of split signals ranged from 10% to 20%. In 
the present issue of Journal of Thoracic Oncology, Martin 
et al.13 reported that borderline cases were associated with 
patterns of split signals. They measured the distances of the 
FIGURE 1.  Diagnostic algorithm for 
ALK rearrangement from guidance 
for ALK gene testing in lung cancer 
patients, presented by the Japanese 
Lung Cancer Society. ALK, anaplastic 
lymphoma kinase.
TABLE 1.  Studies of more than 500 Tumors in which Simultaneous ALK Testing for both IHC and FISH was Performed
ETOP Japan Cabillic et al. Ali et al.
Patients
Resected Stage  
I–III Tumors
EGFR-Negative,  
Crizotinib Ready
Advanced  
Disease
Consecutive  
NSCLC
No. 1281 (240) 2337 2714 522
FISH method Vysis ALK break-apart FISH Vysis ALK break-apart FISH Vysis ALK break-apart FISH, 
and Dako split probe
Vysis ALK break-apart FISH
IHC Clone 5A4 5A4 5A4 D5F3
IHC detection system Novolink, Leica Biosystems Envision Flex+, Dako and 
iAEP, Nichirei
UltraView and OptiView 
systems, Ventana
OptiView and OptiView 
amplification system, Ventana
Discrepant IHC/FISH 52 (21%) 48 (2%) 55 (2%) 2 (0.3%)
  FISH-/IHC+ 52 12 19 0
  FISH+/IHC- 0 36 36 2
Sensitivitya 35% 86% 68% 90%
Specificitya 100% 99% 99% 100%
Positive prediction valuea 100% 95% 81% 100%
Negative prediction valuea 25% 98% 99% 99%
aExpectation of IHC power for FISH standard.
EGFR, epidermal growth factor receptor; ETOP, European Thoracic Oncology Platform; NSCLC, non–small-cell lung cancer; IHC, immunohistochemistry; ALK, anaplastic 
lymphoma kinase; FISH, fluorescent in-situ hybridization.
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split signals and found them to be continuous with a cut-off 
value of 15%. Furthermore, the split distances were different 
between ALK-positive and ALK-negative tumors, with sig-
nificantly shorter split patterns in ALK-negative and border-
line ALK-positive tumors, with borderline tumors defined as 
having 30% or less ALK rearranged cells. Interestingly, three 
of those tumors with borderline positivity in FISH did not 
show a positive reaction with ALK IHC.
As an excellent response can be achieved with molecu-
larly targeted treatment of driver mutations, it is essential to 
accurately identify eligible patients. Unfortunately, the inci-
dence of tumors with ALK rearrangement is limited to 4% 
of non–small-cell lung cancer cases, thus selection is diffi-
cult. Importantly, results of large cohorts in clinical investi-
gations indicate that some non–small-cell lung cancer cases 
(0.2–21%) show discordant results between IHC and FISH, 
implying that a single assay strategy can lead to inadequate 
selection of patients. Particular attention should be paid to 
cases with borderline results in FISH analysis, which have 
been found to be related to discrepant findings, thus adding 
IHC analysis might be recommended. In turn, IHC findings 
show similar pitfalls in regard to discrepancies, though few 
instances have been reported. Detailed studies of IHC discrep-
ant cases are warranted.
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TABLE 2.  Possible Mechanisms Related to False-Positive and False-Negative Results
False-Positive False-Negative
IHC Nonspecific staining (particularly to mucin)
High-grade neuroendocrine tumor
Mucin-rich cells (signet ring cells)
Technical issues (poor fixation, insensitive detection method, etc.)
FISH Tissue sectioninga Compressed z-stacked images
Atypical signal profile
aIn sectioning paraffin-blocks, tumor cell nuclei in the tissues are always sliced into several sections, because section thickness is approximately 4 μm in contrast to 20 μm or more 
of the tumor nuclei. Therefore, it could be possible to make FISH signals on the sectioning surface separated, resulting in imitated break-apart signals.
IHC, immunohistochemistry; FISH, fluorescent in-situ hybridization.
